CD44 loss of function sensitizes AML cells to the BCL-2 inhibitor venetoclax by decreasing CXCL12-driven survival cues.

Yu, XB; Munoz-Sagredo, L; Streule, K; Muschong, P; Bayer, E; Walter, RJ; Gutjahr, JC; Greil, R; Conch, ML; Muller-Tidow, C; Hartmann, TN; Orian-Rousseau, V.

Blood. 2021 Sep 23;138(12):1067-1080. doi: 10.1182/blood.2020006343.

https://pubmed.ncbi.nlm.nih.gov/34115113/